Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Microbiome-Microglia interaction in Alzheimer's disease

Project description

Microbiota and microglial interaction in Alzheimer’s disease progression

Alzheimer’s disease (AD) affects over 55 million people globally and has no effective treatment. Microglial cells involved in amyloid-beta clearance and neuroinflammation play a key role in AD progression. Recent evidence suggests that gut microbiota may influence these cells, but the mechanisms underlying the role of the gut-microbiota-brain axis in AD remain unclear. With the support of the Marie Skłodowska-Curie Actions programme, the MiMi-AD project will elucidate how gut microbiota regulates microglial reactivity in AD progression, using the Tg2576 mouse model. It will investigate whether exercise-induced changes in gut microbiota can facilitate microglial cells in enhancing amyloid-beta (Aβ) clearance, slowing cognitive decline and reducing neuroinflammation. Findings may support new biomarker identification and new therapeutic strategies for delaying AD onset.

Objective

Alzheimer’s disease (AD) affects over 55 million people worldwide, with no effective treatments currently available. Understanding early-stage mechanisms of the disease is critical to developing new therapeutic approaches. Microglial cells, key regulators of amyloid-beta (Aβ) clearance and neuroinflammation, are implicated in the progression of AD. Emerging evidence suggests that the gut microbiota, through its influence on microglial function, may play a pivotal role in AD pathogenesis. However, the precise regulatory mechanisms of the gut-microbiota-brain axis in AD remain unexplored.
The MiMi-AD project, aims to elucidate the role of gut microbiota in modulating microglial activity across AD progression stages, using the Tg2576 mouse model of AD. Specifically, the project will investigate whether exercise-induced alterations in gut microbiota can prime microglial cells to promote Aβ clearance, delay cognitive decline, and reduce neuroinflammation. The research will employ cutting-edge transcriptomics, metabolomics, and microbiota analysis to explore these dynamic interactions, along with in vivo and in vitro studies to identify targetable microbial metabolites.
The outcomes of this research could identify novel gut-brain axis pathways, providing a foundation for therapeutic strategies aimed at delaying the onset of AD. Through interdisciplinary collaboration, this project aligns with European and global priorities in promoting healthy aging, offering potential benefits for individuals at risk of developing AD.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-PF-EF - HORIZON TMA MSCA Postdoctoral Fellowships - European Fellowships

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-PF-01

See all projects funded under this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 226 420,56
Address
RUE MICHEL ANGE 3
75794 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data